Epidiolex can be prescribed at general hospitals in Korea
By Eo, Yun-Ho | translator Choi HeeYoung
21.04.27 16:09:23
가나다라
0
Epidiolex passed DC at SNHU, where there are many patients with epilepsy
There are problems such as supply and demand issues and the demand to expand the standard of benefits
According to related industries, Epidiolex (Cannabidiol, CBD Oil), a hemp-based drug for the treatment of patients with rare and intractable diseases among children with epilepsy, has passed the drug commitee (DC) of Seoul National University Hospital.
Epidiolex has been reimbursed this month. Since this drug was recognized as an urgently introduced drug by the MFDS in March 2019, it has been struggling to register benefits.
With the application of this benefit, the drug cost to be taken by patients has been significantly reduced from about ₩6.7 million per three months to ₩440,000. However, for patients
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)